Literature DB >> 15777558

The common insertional polymorphism in the APOC1 promoter is associated with serum apolipoprotein C-I levels in Hispanic children.

Neil S Shachter1, Daniel Rabinowitz, Sheldon Stohl, Karin Conde-Knape, Jeffrey S Cohn, Richard J Deckelbaum, Lars Berglund, Steven Shea.   

Abstract

We examined the effect of APOC1-317insCGTT allele status (HpaI RFLP, deletion [H1] and insertion [H2] alleles) on serum apolipoprotein (apo) C-I level in 362 Hispanic children in the Columbia University BioMarkers Study. The H2 allele was present in 147 subjects (40.6%). Serum apoC-I was 20% lower in the presence of the H2 allele in APOE epsilon3/epsilon3 homozygotes (P=0.003) but did not differ by H2 status in epsilon4 carriers. Insufficient numbers of epsilon2 carriers (N=45) were present for analysis. In multivariate analysis in the epsilon3/epsilon3 context, after adjusting for potential covariate effects and familial aggregation, the mean effect of H2/* versus H1/H1 on apoC-I level, was estimated to be 2.15+/-0.55mg/dl (P<0.0025). Plasma triglyceride level was weakly correlated with serum apoC-I level (Pearson's r=0.17, P<0.001) but was highly correlated with serum apoC-III (Pearson's r=0.74, P<0.0001). Nevertheless, presence of the H2 allele was not significantly associated with serum apoC-III level. Thus, the effect of APOC1 genotype on serum apoC-I level was not due to apoC-I level serving as a surrogate for triglyceride level. The APOC1-317insCGTT allele is a commonly polymorphic genetic marker that is associated with serum apoC-I level in the APOE epsilon3/epsilon3 context. These findings suggest that the mechanism of the previously described association with plasma TG is, at least in part, related to the correlation of the polymorphism with the level of expression of apoC-I.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15777558     DOI: 10.1016/j.atherosclerosis.2004.10.032

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  6 in total

1.  Plasma apolipoprotein CI correlates with increased survival in patients with severe sepsis.

Authors:  Jimmy F P Berbée; Caroline C van der Hoogt; Carla J C de Haas; Kok P M van Kessel; Geesje M Dallinga-Thie; Johannes A Romijn; Louis M Havekes; Henk J van Leeuwen; Patrick C N Rensen
Journal:  Intensive Care Med       Date:  2008-01-30       Impact factor: 17.440

2.  APOC1 T45S polymorphism is associated with reduced obesity indices and lower plasma concentrations of leptin and apolipoprotein C-I in aboriginal Canadians.

Authors:  Piya Lahiry; Henian Cao; Matthew R Ban; Rebecca L Pollex; Mary Mamakeesick; Bernard Zinman; Stewart B Harris; Anthony J G Hanley; Murray W Huff; Philip W Connelly; Robert A Hegele
Journal:  J Lipid Res       Date:  2009-10-06       Impact factor: 5.922

3.  Sitagliptin Results in a Decrease of Truncated Apolipoprotein C1.

Authors:  Nicole E B Skinner; Matthew S Wroblewski; Julie A Kirihara; Gary L Nelsestuen; Elizabeth R Seaquist
Journal:  Diabetes Ther       Date:  2015-07-22       Impact factor: 2.945

4.  Feasibility of ApoC1 serum levels as tumor biomarker in glioblastoma patients: a pilot study.

Authors:  Michelle Hilbert; Peter Kuzman; Wolf C Mueller; Jürgen Meixensberger; Ulf Nestler
Journal:  Sci Rep       Date:  2022-10-10       Impact factor: 4.996

5.  Apolipoprotein C-I is an APOE genotype-dependent suppressor of glial activation.

Authors:  Eiron Cudaback; Xianwu Li; Yue Yang; Thomas Yoo; Kathleen S Montine; Suzanne Craft; Thomas J Montine; Christopher Dirk Keene
Journal:  J Neuroinflammation       Date:  2012-08-10       Impact factor: 8.322

6.  Effects of apoC1 genotypes on the hormonal levels, metabolic profile and PAF-AH activity in Chinese women with polycystic ovary syndrome.

Authors:  Renjiao Zhang; Qingqing Liu; Hongwei Liu; Huai Bai; Yujin Zhang; Linbo Guan; Ping Fan
Journal:  Lipids Health Dis       Date:  2018-04-10       Impact factor: 3.876

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.